摘要
【目的】:
通过监测急性重型颅脑损伤患者急性期血清中神经元特异性烯醇化酶(NSE)、基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)水平的动态变化规律,探讨其与病情演变、治疗预后的相关性临床意义。
【方法】:
采用前瞻性对比研究方法收集重型颅脑损伤患者共86例及对照组20例。采用ELISA法检测血清中NSE、MMP-2及MMP-9水平,分析其变化趋势,结合GOS评分及预后情况进行分析比较。
【结果】:
总体监测重型颅脑损伤后患者血清NSE、MMP-2及MMP-9蛋白浓度在各时间点显著高于对照组(P<0.01)。其中NSE浓度高峰出现在第5天,此后至第7天仍处于较高水平,NSE浓度趋势与GCS评分变化呈负相关,相关系数r=﹣0.117。MMP-2、MMP-9浓度在外伤后的第1天即出现升高,第1次高峰出现在第3天,第2次高峰出现第5天,第7天有所下降,但仍显著高于对照组。GCS3-5分与GCS6-8分组对照中,MMP-2浓度值在各监测点(均前组大于后组),P<0.01,组间差异有显著性差异。NSE及MMP-9中,P>0.01,差异没有统计学意义,提示MMP-2在早期评估颅脑损伤程度的价值优于NES及MMP-9。预后不良组患者伤后第1、3、5、7天血清MMP-2、MMP-9浓度显著高于相同时间点的预后良好组患者(P<0.01),NSE在两组对照中差异也有统计学意义。根据ROC曲线结果:MMP-9检测的在预后评估中价值最高,其次为MMP-2,而NSE预测价值最差。
【结论】:
血清NSE、MMP-2、MMP-9蛋白测定对于早期评估重型颅脑损伤的严重程度有重要意义,可以提示颅脑外伤患者病情变化,为临床颅脑损伤患者的诊治提供新的指标,且可作为预后评估重要检测手段。
Objective:
To investigate the changes in the serunm levels of neuron specific enolase and matrix metalloproteinases-2 and matrix metalloproteinases-9 and their clinical indications in the patients after severe traumatic brain injury.
Method:
A prospective control study was carried out.The serunm from 56 sTBI patients and 20 normal persons were collected to measure the levels of NSE、MMP-2 and MMP-9 by using ELISA and analyzed the change trend of them together with Glasgow Outcome Scale.
Result:
The serum levels of NSE、MMP-2 and MMP-9 were significantly higher in the brain trauma group than those in the control group(P<0.01). The serum levels of NSE peaked on 5th day,although dropping on the 7th day after brain trauma ,was significantly higher in the brain trauma group than that in the control group. The serum levels of MMP-2、MMP-9 peaked on 1st day and the second peak appeared on 5th day and than dropping on 7th day. The serum levels of NSE、MMP-2 and MMP-9 were significantly higher in the patients with poor prognoses group than those with good prognoses group(P<0.01).
Conclusion:
NSE、MMP-2 and MMP-9 of the serum were involved in the pathological process of acute brain injury, and might play an important role in secondary brain injury .Determination of their contents was of clinical importance for evaluation of the severity of injury and outcome prediction.
引文
1.王忠诚主编,神经外科学.武汉:湖北科学技术出版社,2005.
2. Royds JA, Taylor CB, Timperley WR. Enolase isoenzymes as diagnostic markers. Neuropathol ApplNeurobiol, 1985, 11(1):1-16.
3. Qu inn GB, Reeves IG, Day IN. Mapping of antigenic sites inhuman neuron-specific enolase by express ionsubclon ing. ClinChem , 1994, 40(5):790-795.
4.郭广宏,王建柱,丁慧,等ELISA法检测肿瘤相关抗原神经元特异性烯醇化酶的方法学评价.标记免疫分析与临床2009, 16 (4) :247 -249.
5. Pelink a LE, Hertz H, Mauritz W, etal. Nonspecific increase of system ic neuron-specific enolase after trauma clinical and experimental findings. Shock, 2005, 24(2):119-23.
6. Rachel PB, Mary CP, Stephen RW, etal. Neuron-specific enolase and S 100B in cerebrospinal fluid after severe traumatic brain injury in in fants and children. Pediatrics, 2002,109(2):E31.
7.关伟,王东,李增鹏等多肿瘤标志物蛋白芯片检测及判别函数在妇科肿瘤诊断中的应用.重庆医学,2009, 38(18):2324-2328.
8.董娜,孙雷娜,战忠利等肺鳞状细胞癌伴神经内分泌分化与生物学特性及预后关系探讨.中国肿瘤临床,2009, 36(20):1171-1175.
9. Chiaretti A, BaroneG, RiccardiR, etal. NGF, DCX andNSE upregulation correlates with severity and outcome of headtrauma in children. Neu rology, 2009, 72(7):609-616.
10. Visse R,Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry [ J ].Circ Res, 2003, 92 (8) : 8272839.
11. Mandal M,Mandal A,Das S,et al.Clinical implications of matrix metalloproteinases.Mol Cell Biochem,2003,252(1-2):205~329
12. Malemud CJ,Matrix metalloproteinases(MMPs)in healthand disease:an overview.Front Biosci,2006,11(1):1696~1701
13. Fater M, Stroick M, Griebe M, et al. Matrix metalloproteinases in cerebrovascular diseases [J]. Cerebrovasc Dis,2005, 20:141-151.
14. Pfefferkom T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloputeinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion [J]. Stroke,2003,34(8):2025-2030.
15. Rosenberg GA. Matrix metalloproteinase in neuroinflammation[J]. Glia,2002,39(3):279-291.
16. Rosenberg GA. Matrix metalloproteinases in brain injury[J]. J Neurotrauma,1995,12(5):833-842
17. Canete Soler R ,et al. Brain Res Dev Brain Res ,1995 ;88(1) :37
18.李玉斌刘运生基质金属蛋白酶与脑创伤国外医学神经病学神经外科分册2004,31(3):244-247
19.Moir EM,Adcock KH,Morgenstem DA,etal.Matrix metalloproteinases and their inhibitors are Produced by overlapping populations of activated astrocytes.Brain Res Mol BrainRes,2002,100(l-20):103-117
20.TanakaM,ItaiT,AdachiM,etal.Down regulation of Fas ligand by shedding.Nat Med,1998,4:31一36
21.SchneiderP,HollerN,BodmerJL,etal.Conversion of membrane-boundFas(CD95)ligand to its soinble formisas soeiated with down regulation of its proapoptotic activity and loss of liver toxicity.JExpMed,1998,187:1205-1213.
22. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia [J]. Glia,2005,50(4):329-339.
23. Zoppo GJ, Milner R, Mabuchi T, et al. Microglial activation and matrix protease generation during focal cerebral ischemia [J]. Stroke,2007,38(2):646-651.
24. Rosenberg GA, Dencoff JE, Correa N, et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis:relation to blood-brain barrier injury [J]. Neurology,1996:46(6):1626-1632.
25. Fujimura M, Gasche Y, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase -9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion [J]. Brain Res,1999,842(1):92-100.
26. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9[J]. J Clin Invest,2004,113(10):1447-1455.
27. Kim GW, Gasche Y, Grzeschik S, et al. Neurodegeneration in striatum induced by the mitochondrial toxin3-nitropropionic acid: role of matrixmetalloproteinase-9 in early blood-brain barrier disruption [J]. J Neurosci,2003,23(25):8733-8742.
28. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of bloodbrainbarrier and white matter components after cerebralischemia [J]. J Neurosci,2001,21(19):7724-7732.
29. Rosenberg GA, Navratil M, Barone F, et al. Proteolytic casecade enzymes increase in focal cerebral ischemia inrat [J]. J Cereb Blood Flow Metab,1996:16(3):360-366.
30. Berger RP, Dulani T, Adelson PD, etal. Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers:a possible screening tool.2006,Pediatrics 117(2):325-332
31. Casmiro M, Maitan S, De Pasquale F, etal. Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur J Neurol 2005,12(5):369-374
32. Bandyopadhyay S, Hennes H, Gorelick MH, eta1.Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury.Acad Emerg Med,2005,12(8):732-738.
33. Vos PE,Lamers KJ,Hendriks JC,eta1.Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury [J].Neurology.2004,62(8):1303—1310.
34.杨喜民,李迎国,朱剑功,等.脑外伤患者NSE和MBP含量变化及黄芪的作用研究[J ].现代检验医学杂志, 2008, 23(3):101.
35. Fater M,Stroick M,Griebe M,etal.Matrix metalloproteinases in cerebrovascular diseases [J].Cerebrovasc Dis,2005,20:141-151.
36. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia [J]. Glia,2005,50(4):329-339.
37. Gursoy-Ozdemir Y,Qiu J,Matsuoka N,etal.Cortical spreading depression activates and up-regulates MMP-9[J].J Clin Invest,2004,113(10):1447-1455.
38.宋林杰,张秀萍,王翀等,大鼠弥漫性脑损伤后脑组织中MMP-9的表达与神经元损伤.中国临床神经外科杂志,2008,Vol13,No5:292-295.
39.崔向宁,尹岭,王玉来等,创伤性脑损伤大鼠脑组织基质金属蛋白酶的表达.中华老年心脑血管病杂志,2008,Vol10 ,No.1:53-56.
1.Visse R,Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry [ J ].Circ Res, 2003, 92 (8) : 8272839.
2. Mandal M,Mandal A,Das S,et al.Clinical implications of matrix metalloproteinases.Mol Cell Biochem,2003,252(1-2):205~329
3. Malemud CJ,Matrix metalloproteinases(MMPs)in healthand disease:an overview.Front Biosci,2006,11(1):1696~1701
4. Canete Soler R ,et al. Brain Res Dev Brain Res ,1995 ;88(1) :37
5. Pfefferkom T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloputeinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion [J]. Stroke,2003,34(8):2025-2030.
6. Rosenberg GA. Matrix metalloproteinase in neuroinflammation[J]. Glia,2002,39(3):279-291.
7. Rosenberg GA. Matrix metalloproteinases in brain injury[J]. J Neurotrauma,1995,12(5):833-842
8. Fater M, Stroick M, Griebe M, et al. Matrix metalloproteinases in cerebrovascular diseases [J]. Cerebrovasc Dis,2005, 20:141-151.
9. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia [J]. Glia,2005,50(4):329-339.
10. Zoppo GJ, Milner R, Mabuchi T, et al. Microglial activation and matrix protease generation during focal cerebral ischemia [J]. Stroke,2007,38(2):646-651.
11. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of bloodbrainbarrier and white matter components after cerebralischemia [J]. J Neurosci,2001,21(19):7724-7732.
12. Fujimura M, Gasche Y, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase -9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion [J]. Brain Res,1999,842(1):92-100.
13. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9[J]. J Clin Invest,2004,113(10):1447-1455.
14. Kim GW, Gasche Y, Grzeschik S, et al. Neurodegeneration in striatum induced by the mitochondrial toxin3-nitropropionic acid: role of matrixmetalloproteinase-9 in early blood-brain barrier disruption [J]. J Neurosci,2003,23(25):8733-8742.
15. Rosenberg GA, Dencoff JE, Correa N, et al. Effect of steroids onCSF matrix metalloproteinases in multiple sclerosis:relation to blood-brain barrier injury [J]. Neurology,1996:46(6):1626-1632.
16. Rosenberg GA, Navratil M, Barone F, et al. Proteolytic casecade enzymes increase in focal cerebral ischemia inrat [J]. J Cereb Blood Flow Metab,1996:16(3):360-366.
17. Matter K,Balda MS.Functional analysis of tight junctions. Methods, 2003,30(3):228~234
18. MoriT,WangX,Aoki T,et al.Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic braininjury.J Nerotrauma,2002,19(11):1411~1419
19. Kawai N,Kawanishi M,Okada M,et al.Treatment of cold injury-induced brain edema with a nonspecific matrixmetalloproteinase inhibitor MMI207 in rats.J Neurotrauma,2003,20(7):649~657
20. Chen ZL,Indyk JA,Strickland S.The hippocampal laminin matrix is dynamic and critical for neuronal survival.Mol Biol cell,2003,14(7):2665~2676
21. Rosenberg GA. Matrix metalloproteinase in neuroinflammatio[J]. Glia,2002,39(3):279-291
22. Frisch SM,Screaton RA.Anoikismechanisms[J].Curropin Cell Bio,2001, 13(5):555~562.
23. Cardone MH,Salvesen GS,Wiomann C,et al.The regulation of anoikisMEKK-1 activation requires cleavage by caspases [J].Cell1997,90(2):315~323.
24. Gu Z,Kaul M,Yan B,et al.S-nitorsylation of matrix metalloproteinases signsling pathway to neuronal cell death [J],Science,2002,297(5584):1186~1190.
25. Gu Z,Cui J,Brown S,et al.A highly specific inhibitor of matrix metalloproteinase-9 rescues minin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia [J].J Neurosci,2005,25(27):6401~6408.
26. Ghislain Opdenakker,Philippe E.Van den Steen,Benedicte Dubois,et al.Gelatinase B functions as regulator and effector in leukocyte biology[J].J Leukoc Biol,2001,69(6):851~859
27. Gasche Y,Copin JC,Sugawara T,et al.Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia[J].J Cereb Blood Flow Metab,2001,21(12):139~140 30 Dzwonek J,Rylski M,Kaczmarek L.Matrix metalloproteinase and their endogenous inhibitors in neuronal physiology of the adult brain[J].FEBS Lett,2004 567(11):129~135
28. Inoue K,Slaton JW,Kim SJ,et al.Interleukin 8 expression regulates tumor igenicity and metastasis in human bladder cancer[J].Cancer Res,2000,60(8):2290~2299
29. Bond M,Fabunmi RP,Baker AH,etal.Synergistic upregulation ofmetalloproteinase-9 by growth factors and inflammatory cytokines:an absolute reauirement for transcription factor NF-kappa B[J].FEBS Lett,1998,435(1):29~34
30. Mohan MJ,Seaton T,Mitchell J,et al.The tumor necrosis factor alpha converting enzyme(TACE):a unique metalloproteinase with highly defined substrate selectivity[J].Biochemistry,2002,41(30):9462~9469
31. Vaday GG,Hershkoviz R,Rahat MA,et al.Fibronectin bound TNF-alpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis[J].J Leukoc Biol,2000,68(5):737~747
32. Vecil GG,Larsen PH ,Corley SM ,et al . Interleukin21 is a key regulator of mat rix metalloproteinase29 expression in humanneurons in culture and following mouse brain trauma in vivo.Neurosci Res ,2000 ,2 :2122224.
33. Caroline HA ,Stephen CR ,Robert JM ,et al . TNF2αregulates epit -helial expression of MMP-9 andαvβ6 during tumour promotion. A role for TNF2-αin keratinocyte migration ? Oncogene ,2004 ,23 :695426966
34. Gidday JM , Gasche YG, Copin JC , et al . Leukocyte2derived mat rix metalloproteinase29 mediates blood2brain barrier breakdown and is proinflammatory following t ransient focalcerebral ischemia. Am J Physiol Heart Circ Physiol , 2005 ,289 :5582568.
